No se kvartteri ei mennyt ihan putkeen. 
Wellness
- alustan kaupallistamisessa merkittävää viivästystä, minkä takia kasvu sakannut
- Investointeja ilmeisesti jouduttu lisäämään ja tulot jääneet jälkeen
- Saksa ja Ruotsi saatu avattua vihdoin lokakuun lopussa
- Uusi tilaus UK:ssa Nexa-AI:n kanssa pari viikkoa go-liven jälkeen
Lifecare
- Kasvua saatu aikaan viime vuoteen, ei kuitenkaan enää tämän vuoden aikana
- Bruttokate hyvällä tasolla
Yleisesti
- Kassavirta jäi edelleen pakkaselle
- Investointikulut kasvussa
- Kasvu pysähtyi, Wellness jarruna
This quarter has seen us navigate a challenging environment with steady progress, while addressing temporary setbacks in Wellness and implementing several initiatives to position the Group for future growth.
Third quarter: 1st July – 30th September 2024
- Revenue increased by 1 per cent to generate total sales of EUR 3.9 (EUR 3.9m). This growth was achieved in the Lifecare division (7 per cent) but was offset by a contraction within the Wellness division (9 per cent).
- Subscription revenue increased 12 per cent (EUR 0.3m) to EUR 3.3m and now makes up 84 per cent of total group revenue, a significant increase from the prior year’s comparative of 75 per cent.
- Adjusted EBITDA of EUR 0.9m (EUR 1.1m) was generated resulting in an Adjusted EBITDA margin of 23 per cent (27 per cent).
- Adjusted operating loss of EUR 0.2m (profit EUR 0.1m) was generated resulting in a margin of -6 per cent (3 per cent).
- Adjusted ordinary and diluted profit per share totaled EUR (0.02) (EUR 0.00).
- Cashflow generated from operations before the payment of adjusting items equaled EUR 0.8m (EUR 0.9m).
- Free cash flow for the quarter was a net outflow of EUR 0.4m (outflow EUR 0.3m).
Key highlights during and subsequent to the third quarter
The Lifecare division has demonstrated remarkable and consistent profitability, particularly in Physitrack platform subscription sales to the MSK rehabilitation segment, expanding its influence across both public and private healthcare
sectors. The division has firmly positioned itself as a leading provider of software for injury prevention and recovery solutions, ensuring its ongoing relevance in the evolving healthcare landscape.In the Wellness division, innovation, talent acquisition, and successful integration of acquired businesses have been key drivers of its early growth, with acquired companies scaling 3-4times post-acquisition. However, challenges have arisen due to delays in the international rollout of Champion Health’s software, slowing the Wellness division’s growth. Despite this, significant progress has been made with Swedish and German market entries in October, and
long-term prospects for Champion Health remain strong.Looking ahead, the Lifecare division continues to enhance its market share by providing market-leading solutions that address emerging healthcare needs. Meanwhile, with international Champion Health versions launched at the end of October, the Wellness division is set to be well-positioned for rapid expansion with new products and markets that empower health and wellbeing, allowing the company to capitalise on the rising demand for digital health solutions.
CEO:n kommenteista poimittuna
The internationalisation of Champion Health, a uniquely holistic data-focused and ultra-personalised employee wellness solution, was especially key to continuing the strong Wellness growth journey that we set out on in 2021. Unfortunately, due to the Champion Health launch delays, we have been unable to put this software into the hands of the Wellness entrepreneurs that generated our amazing growth in 2021-2023 as quickly as planned, which has led to our expansion strategy slowing down. This is, of course, disappointing for all of us who were keen to bring Champion Health to a broader audience and accelerate its impact
Nevertheless, I want to assure you that this delay is only temporary, and our commitment to ensuring a successful launch is unwavering, with the Swedish and German releases having been executed at the end of October. Following this, we are taking deliberate steps to refine our approach and strengthen our position in these new markets.
Nähdäkseni sijoituscase on viiveestä huolimatta kuitenkin ennallaan. Viivästys aiheuttaa kuluja ja siirtää tuottoja tulevaisuuteen. Alusta on nyt kuitenkin pystyssä sekä ensimmäinen tilaus jo julkaistu.
Wellnessin pitää kuitenkin alkaa toimittamaan uusia tilauksia ja kasvua, jotta tästä tulee oikeasti jotain järkevää ajan kanssa.
Lifecare jatkaa tasaista toimittamista, siinä ei mitään uutta.
Edit, vielä taseesta:
- Deferred consideration mennee lähelle nollaa vuoden lopussa. Eli lainaa ei ole niin paljon todellisuudessa, kuin tase näyttää. Tulossidonnaiset palkkiot eivät toteudu monelta osin ja tämän takia Q4 EPS varmaan taas aika paljon plussalla.
- Q4 kassavirran pitäisi kääntyä plussalle, kun investoinnit vähenee. Anteja ei pitäisi olla tulossa, ollut pitkälti CEO:n periaatteena, että kasvu tehdään omalla tulorahoituksella.